Browsing Category
Featured Articles
FDA approves the first treatment option for generalized pustular psoriasis flares in adults
Boehringer Ingelheim announced the U.S. Food and Drug Administration has approved SPEVIGO, the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults.…
Read More...
Read More...
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood…
Novo Nordisk and Forma Therapeutics, Holdings Inc. announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for USD 20 per…
Read More...
Read More...
Novartis announces intention to separate Sandoz business to create a standalone company by way of a…
Novartis announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off.
The spin-off aims…
Read More...
Read More...
Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated…
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung…
Read More...
Read More...
Gilead Sciences to Acquire MiroBio
Gilead Sciences, Inc. and MiroBio announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in…
Read More...
Read More...
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi (tafasitamab-cxix)…
Pfizer Inc., MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG, and Incyte (NASDAQ:INCY) today announced a clinical trial collaboration and supply agreement to investigate…
Read More...
Read More...
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
GSK plc announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston,…
Read More...
Read More...
Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
Evotec SE announced the signing of a definitive agreement under which Evotec will acquire 100% of the capital of Rigenerand Srl, a leading cell technology company, for a purchase price…
Read More...
Read More...
Servier Announces FDA Approval of TIBSOVO (ivosidenib tablets) in Combination with Azacitidine for…
Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO …
Read More...
Read More...
Pfizer to Acquire Biohaven Pharmaceuticals
Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of…
Read More...
Read More...
Novartis Kymriah receives EC approval as first CAR-T cell therapy for adults with relapsed or…
Novartis announced that the European Commission (EC) has approved Kymriah (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r)…
Read More...
Read More...
Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to…
Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, announced an expansion of…
Read More...
Read More...
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of…
Pfizer Inc. and BioNTech SE announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the…
Read More...
Read More...
European Commission Approves PADCEV (enfortumab vedotin) for Locally Advanced or Metastatic…
Astellas Pharma Inc. and Seagen Inc. announced that the European Commission (EC) has approved PADCEV (enfortumab vedotin) as monotherapy for the treatment of adult patients with locally…
Read More...
Read More...
UCB expands innovation footprint with new state-of-the-art gene therapy facility
UCB announced it will build an innovative and environmentally sustainable gene therapy process development and clinical manufacturing facility on their high-tech campus in Braine…
Read More...
Read More...
Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy…
Novartis announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids…
Read More...
Read More...
Pfizer Granted FDA Breakthrough Therapy Designation for RSV Vaccine Candidate
Pfizer Inc. announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the US Food and Drug…
Read More...
Read More...
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to…
Read More...
Read More...
Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport…
Eli Lilly and Company announced the launch of the Lilly Institute for Genetic Medicine and an investment of approximately $700 million to establish a state-of-the-art facility at a new…
Read More...
Read More...
Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active…
Read More...
Read More...